Benchmark sees 31% upside in Tabula Rasa in premarket analyst action

|By:, SA News Editor

Tabula Rasa Healthcare (NASDAQ:TRHC) initiated with Buy rating and $85 (31% upside) price target at Benchmark.

Molina Healthcare (NYSE:MOH) upgraded to Overweight with a $142 (20% upside) price target at MUFG. Upgraded to Overweight at JPMorgan.

DaVita (NYSE:DVA) upgraded to Neutral with a $59 (9% upside) price target at UBS. Shares up 1% premarket.

Loxo Oncology (NASDAQ:LOXO) downgraded to Market Perform at Cowen and Company after Lilly bid.

Diplomat Pharmacy (NYSE:DPLO) downgraded to Hold with a $15 (19% upside) price target at Lake Street citing a deceleration in growth and uncertainties with leadership.

Subscribe for full text news in your inbox